4%四钠EDTA预防中心静脉通路装置相关并发症:一项随机临床试验
这项实用型、三盲、多中心、整群随机交叉试验在6家加拿大医院(3家社区医院、3家学术中心)的ICU开展,纳入1574例符合条件的成人患者,最终分析1468例(平均年龄60岁,37.7%女性),比较4%四钠EDTA封管液与对照封管液(生理盐水,血液透析管路用4%枸橼酸盐)。主要复合终点(导管相关血流感染、需阿替普酶处理的导管堵塞、因堵塞拔管)发生率:t-EDTA组13.1/1000导管日(74例事件)vs 对照组19.9/1000导管日(126例事件),校正后率比0.68(95%CI 0.47-0.96,P=0.03)。三个组分中仅需阿替普酶的导管堵塞存在显著差异(66 vs 112;发生率11.67 vs 17.73/1000导管日;率比0.66,95%CI 0.46-0.96)。作者结论认为,与对照封管液相比,4% t-EDTA封管液降低了该复合终点发生率。
要点
- ICU成人留置CVAD且至少1个管腔未使用:4% t-EDTA封管组主要复合终点13.1/1000导管日(74例事件),对照组19.9/1000导管日(126例事件),校正率比0.68(95%CI 0.47-0.96,P=0.03)。
- 复合终点三个组分中,仅需阿替普酶的导管堵塞显著减少:t-EDTA组66例 vs 对照组112例,发生率11.67 vs 17.73/1000导管日,率比0.66(95%CI 0.46-0.96)。
- 干预方式为预充、外观一致的2.5 mL封管液注射器,t-EDTA组用4%四钠EDTA,对照组用生理盐水,血液透析管路对照用4%枸橼酸盐。
- 试验为实用型、三盲、多中心、整群随机交叉设计,6家加拿大医院(3家社区、3家学术中心)ICU参与,每阶段3.5个月、洗脱随访1个月。
适用人群与场景
- ICU中年龄大于18岁、留置中心静脉通路装置且至少1个管腔未使用的成人患者。
- 6家加拿大医院(3家社区医院、3家学术中心)的ICU,整群随机交叉设计,每阶段3.5个月、随访1个月。
处置流程与药物剂量
- 干预组对所有试验参与者使用预充、外观一致的2.5 mL 4%四钠EDTA(t-EDTA)封管液注射器封管。
- 对照组使用对照封管液:生理盐水;血液透析管路使用4%枸橼酸盐。
- ICU随机分组后使用指定封管液3.5个月,经1个月随访期后交叉至另一组,再使用3.5个月并随访1个月。
研究设计与关键结果
- 研究类型:实用型、三盲、多中心、整群随机交叉试验;6家加拿大医院;1574例符合条件,1468例纳入分析(t-EDTA组696例、对照组772例),平均年龄60岁(SD 16.0),37.7%女性。
- 主要复合终点(CVAD相关血流感染、需阿替普酶处理的导管堵塞、因堵塞拔管):t-EDTA组13.1/1000导管日(74例事件)vs 对照组19.9/1000导管日(126例事件),校正多因素分析率比0.68(95%CI 0.47-0.96,P=0.03)。
- 次要终点中仅需阿替普酶的CVAD堵塞组间显著差异:t-EDTA组66例 vs 对照组112例,发生率11.67 vs 17.73/1000导管日,率比0.66(95%CI 0.46-0.96)。
证据类型、等级与局限
- 证据类型:随机临床试验(实用型、三盲、多中心、整群随机交叉试验);试验注册号ClinicalTrials.gov NCT04548713。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于ICU成人留置CVAD且至少1个管腔未使用的患者,作者结论认为,与对照封管液相比,4% t-EDTA封管液降低了CVAD相关血流感染、需阿替普酶处理的导管堵塞及因堵塞拔管组成的复合终点发生率。
- 主要获益来自需阿替普酶的导管堵塞减少(t-EDTA组66例 vs 对照组112例),其余两个组分未报告组间显著差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Use of central venous access devices (CVADs) can result in catheter-associated bloodstream infection, catheter occlusion, and catheter-related venous thrombosis. EDTA is a potent anticoagulant, antimicrobial, and antibiofilm agent that can be instilled into inactive CVAD ports as a locking fluid to decrease the risk of infection and maintain patency.
OBJECTIVE: To determine whether a 4% tetrasodium EDTA (t-EDTA) locking fluid reduces CVAD-associated infections, occlusions, and thrombolytic use in adults treated in an intensive care unit (ICU).
DESIGN, SETTING, AND PARTICIPANTS: Pragmatic, triple-blind, multicenter, cluster-randomized crossover trial including patients older than 18 years in the ICU with a CVAD in place and at least 1 lumen not in use. The trial was conducted in 6 Canadian hospitals (3 community hospitals and 3 academic centers). The first patient was enrolled on March 22, 2022, and the date of last follow-up occurred on September 25, 2024.
INTERVENTIONS: The ICUs were randomized to use prefilled, identical, masked syringes containing 2.5 mL of t-EDTA (intervention) or control locking fluid (saline or 4% citrate for hemodialysis lines) for all trial participants over a 3.5-month period. After a 1-month follow-up period, ICUs crossed over to the opposing treatment group for another 3.5 months, with a subsequent 1-month follow-up.
MAIN OUTCOMES AND MEASURES: The primary outcome was a composite incidence rate of CVAD-associated bloodstream infection, catheter occlusion requiring alteplase use, and/or catheter removal due to occlusion. Three of the 8 prespecified secondary outcomes included incidence rates of each component of the primary outcome separately.
RESULTS: Of the 1574 eligible patients, 1468 (mean age, 60 [SD, 16.0] years; 37.7% female) were included in the analysis (696 receiving t-EDTA and 772 receiving control). The incidence rate of primary outcome events was 13.1 per 1000 catheter-days (74 events) in the t-EDTA group vs 19.9 per 1000 catheter-days (126 events) in the control group. In adjusted multivariate analysis, the incidence rate of the composite outcome was lower among patients receiving t-EDTA vs control (rate ratio, 0.68; 95% CI, 0.47-0.96; P = .03). Among the 3 components of the primary outcome, only the secondary outcome of CVAD occlusion requiring administration of alteplase significantly differed between the groups, with lower rates in the t-EDTA group vs control (66 vs 112; incidence rate, 11.67 and 17.73 per 1000 catheter-days, respectively; rate ratio, 0.66; 95% CI, 0.46-0.96).
CONCLUSIONS AND RELEVANCE: Compared with control locking solution, use of 4% t-EDTA locking solution for CVADs reduced the incidence of a composite outcome of CVAD-associated bloodstream infection, catheter occlusion requiring alteplase use, and catheter removal due to occlusion among adult patients in the ICU.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04548713.
参考来源
- Ornowska M, Wittmann J, Blitz S, et al. 4% Tetrasodium EDTA to Prevent Central Venous Access Device-Associated Complications: A Randomized Clinical Trial. JAMA. 2026. PMID: 42150112. doi:10.1001/jama.2026.6025
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。